Optimization of Ex Vivo Activation and Expansion of T Cells for Therapy of Lymphoma Via Antagonism of PI3K δ and Vasoactive Intestinal Peptide Signaling
Edmund K. Waller(Emory University), Christopher T. Petersen(St. Jude Children's Research Hospital), Kunhee Lee(Emory University), Todd Sulchek(Georgia Institute of Technology), Cynthia Gaylor(Emory University Hospital), Neera Jagirdar(Emory University), Anna B. Morris(Emory University), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Ashley D. Staton(Emory University), Mojitabe Hassan(Emory Healthcare), Jasmin Jeffery
Cited by 1
Related Papers
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
|Journal of Clinical Oncology|2018|574